TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Vivimed Labs Limited
VIVIMEDLAB Updated about 5 hours ago

Vivimed Labs Limited Share Price

NSE closing price and which mutual funds hold this stock

TopFund Score: 31/100 · Weak See breakdown ↓

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 25 Sep 2026

₹5.55

Change

+0.1 (1.83%)

Open

₹5.5

Prev. Close

₹5.45

Day High

₹5.55

Day Low

₹5.35

Volume Analysis

Traded

14,406

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Promoter holding is falling
  • •Below-average fundamentals quality score (31/100)
  • •Low operating margin (-218.0%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹5.81 ₹5.68 ₹5.61 ₹5.48 ₹5.41 ₹5.28 ₹5.21
Fibonacci ₹5.68 ₹5.6 ₹5.56 ₹5.48 ₹5.4 ₹5.36 ₹5.28
Camarilla ₹5.61 ₹5.59 ₹5.57 ₹5.48 ₹5.53 ₹5.51 ₹5.5

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-66.94%

1 Week

+1.46%

1 Month

-21.5%

3 Months

-4.31%

6 Months

+0.36%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

81.24%

Net margin -251.43% × asset turnover 0.09x × equity multiplier -3.59x

Company Overview

Sector

Healthcare

Market Cap

₹46 Cr

Book Value

₹-25.4

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Vivimed Labs Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 31/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (31/100).

TopFund Score — Fundamentals Quality

31/100 — Weak

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

0

Cash Flow

72

Corporate Governance

10

Momentum

3

Institutional Ownership

32

Business Quality

25

Risk & Volatility

60

Liquidity

0

From Screener.in

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -39.5% over past five years.
  • −Promoter holding is low: 7.57%
  • −Contingent liabilities of Rs.183 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 26 Sep

Vivimed Labs announces 8th CoC meeting on September 29, 2026 under CIRP.

Seeking Time For Holding AGM 26 Sep

Committee of Creditors approved filing for three-month AGM extension for FY2025-26.

Closure of Trading Window 23 Sep 23 Sep
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 08 Sep

Vivimed Labs pre-facto intimation: 7th Committee of Creditors meeting on September 10, 2026.

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 17 Aug

Vivimed Labs schedules 6th CoC meeting on 18 August 2026 via audio-visual mode.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Sales + 37 35 34 41 39 29 25 37 26 21 21 16 12
Expenses + 201 36 40 40 67 40 25 35 28 22 22 27 152
Operating Profit -164 0 -6 1 -28 -11 -1 1 -2 0 -1 -11 -140
OPM % -444.0% -0.9% -18.0% 3.1% -74.0% -37.0% -2.6% 2.9% -10.0% -1.3% -4.6% -68.0% -1,169.0%
Other Income + 1 0 2 0 8 0 0 0 4 0 0 0 6
Interest 9 11 12 13 -33 0 0 0 2 1 2 1 1
Depreciation 96 5 5 5 6 4 4 7 6 5 5 5 12
Profit before tax -268 -16 -20 -17 7 -15 -5 -6 -5 -5 -7 -17 -147
Tax % -1.0% 0.0% 0.0% -3.0% 21.0% 0.0% 0.0% 0.0% 2.0% 0.0% 0.0% 0.0% 0.0%
Net Profit + -266 -16 -20 -16 5 -15 -5 -6 -6 -5 -7 -17 -147
EPS in Rs -32 -2 -2 -2 1 -2 -1 -1 -1 -1 -1 -2 -18
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Sales + 1,380 1,346 1,462 1,186 1,315 1,059 861 237 187 149 116 70
Expenses + 1,156 1,111 1,057 971 1,135 1,049 830 245 374 182 129 222
Operating Profit 224 234 404 215 180 10 32 -8 -187 -33 -13 -152
OPM % 16.0% 17.0% 28.0% 18.0% 14.0% 1.0% 3.7% -3.3% -100.0% -22.0% -11.0% -218.0%
Other Income + 6 11 8 10 23 8 10 1 1 10 4 6
Interest 86 84 68 82 70 61 56 40 36 3 3 4
Depreciation 66 61 58 56 67 67 56 18 108 20 20 26
Profit before tax 78 100 286 86 66 -109 -70 -65 -331 -46 -32 -176
Tax % 7.0% 16.0% 25.0% 11.0% 13.0% 0.0% 3.0% 4.0% -1.0% -1.0% 0.0% 0.0%
Net Profit + 72 84 214 76 57 -109 -72 -68 -329 -45 -32 -176
EPS in Rs 9 10 26 9 7 -13 -9 -8 -40 -5 -4 -21
Dividend Payout % 0.0% 0.0% 2.0% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 479 505 718 885 602 493 415 348 23 -22 -52 -227
Borrowings + 1,076 1,015 1,011 1,149 1,280 1,268 326 359 379 377 376 397
Other Liabilities + 327 519 317 343 431 432 532 543 658 579 580 567
Total Liabilities 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,076 950 921 753
Fixed Assets + 813 814 879 1,035 965 1,045 502 520 436 418 408 386
CWIP 90 94 76 65 122 89 60 40 21 21 17 18
Investments 3 3 3 3 3 86 199 199 199 168 168 181
Other Assets + 992 1,144 1,104 1,290 1,239 990 529 507 421 343 328 170
Total Assets 1,898 2,055 2,062 2,394 2,329 2,210 1,289 1,266 1,076 950 921 753
Equity Capital 16 16 16 17 17 17 17 17 17 17 17 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 140 154 58 21 422 80 567 28 35 -24 -2 8
Cash from Investing Activity + -107 -190 -68 -164 -89 -196 404 -16 -5 28 -5 -1
Cash from Financing Activity + -42 41 35 186 -338 72 -1,015 -10 -34 -6 5 -6
Net Cash Flow -8 4 25 44 -5 -44 -44 1 -3 -2 -1 1
CFO/OP 63 66 23 30 243 972 1,720 -352 -19 73 13 -5
Free Cash Flow 16 95 -11 -142 333 -33 1,084 11 30 -26 -6 7

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 20.94% → 7.57%
  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Public 77.3% 77.29% 77.3% 77.29% 77.3% 77.3% 77.3% 77.3% 90.47% 90.47% 90.47% 90.66%
Promoters 20.94% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94% 7.76% 7.76% 7.76% 7.57%
Government 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
FII 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Vivimed Labs Limited (this stock) 46 — -0.22 —
Mangalam Drug & Chem Ltd 50 — 0.49 -35.2%
Vivo Bio Tech Ltd. 38 — 0.4 -2.0%
Gkb Ophthalmics Ltd. 36 9.69 0.66 3.28%
Medi Caps Ltd. 31 — 0.28 -9.21%
Sunil Healthcare Ltd. 78 21.1 1.12 6.01%
Ortin Global Limited 12 — — —

Which Mutual Funds Hold Vivimed Labs Limited?

Frequently Asked Questions about Vivimed Labs Limited

Community Sentiment

What are other investors saying about Vivimed Labs Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.